Journal article
Geranylgeranyl diphosphate synthase: an emerging therapeutic target
Clinical pharmacology and therapeutics, Vol.90(6), pp.804-812
12/2011
DOI: 10.1038/clpt.2011.215
PMID: 22048229
Abstract
Proteins modified post-translationally by geranylgeranylation have been implicated in numerous cellular processes related to human disease. In recent years, the study of protein geranylgeranylation has advanced tremendously in both cellular and animal models. The advances in our understanding of the biological roles of geranylgeranylated proteins have been paralleled by advances in the medicinal chemistry of geranylgeranylation inhibitors such as those that target geranylgeranyl transferases I and II and geranylgeranyl diphosphate synthase (GGDPS). Although these findings provide the rationale for further development of geranylgeranylation as a therapeutic target, more advanced studies on the efficacy of this approach in various disease models will be required to support translation to clinical studies. This article attempts to describe the advances in (and the challenges of) validation of GGDPS as a novel therapeutic target and assesses the advantages of targeting GGDPS relative to other enzymes involved in geranylgeranylation.
Details
- Title: Subtitle
- Geranylgeranyl diphosphate synthase: an emerging therapeutic target
- Creators
- A J Wiemer - Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USAD F WiemerR J Hohl
- Resource Type
- Journal article
- Publication Details
- Clinical pharmacology and therapeutics, Vol.90(6), pp.804-812
- Publisher
- United States
- DOI
- 10.1038/clpt.2011.215
- PMID
- 22048229
- ISSN
- 0009-9236
- eISSN
- 1532-6535
- Copyright
- © 2011 American Society for Clinical Pharmacology and Therapeutics
- Language
- English
- Date published
- 12/2011
- Academic Unit
- Neuroscience and Pharmacology; Chemistry; Internal Medicine
- Record Identifier
- 9983985886502771
Metrics
13 Record Views